<DOC>
	<DOCNO>NCT02423538</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability single ascending ( SAD ) oral dos SHR0302 compare placebo . Also , pharmacokinetics ( PK ) pharmacodynamics ( PD ) SHR0302 single oral administration evaluate , , applicable , maximum tolerate dose determine .</brief_summary>
	<brief_title>First-in-Human Single Ascending Dose SHR0302</brief_title>
	<detailed_description />
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Healthy subject , age 1845 year ( inclusive ) ; The weight subject 50 kg , body mass index ( BMI = weight/height square ( kg/m2 ) ) within range 19 24 . Any condition might interfere procedure test study History heart failure renal insufficiency Smoking ; Drug alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>